易華錄(300212.SZ):目前易雲未就深圳的具體項目與百度開展合作,但雙方一直保持緊密的業務和研發層面的溝通
格隆匯7月24日丨有投資者向易華錄(300212.SZ)提問,“近期,百度旗下“蘿蔔快跑”無人駕駛項目獲得深圳市授牌,開展商業化運營。而公司此前也報道:易華錄引入百度作為華路易雲(易華錄下屬公司)的戰略投資者後,華路易雲和百度展開了密切合作,以HLYY-OS車路協同操作系統為底盤,打造以車路協同為核心的未來交通系統。請問華錄易雲是否有參與該項目?當前華錄易雲在無人駕駛領域的成果、產品和服務是怎麼樣的?”
易華錄回覆稱,目前易雲未就深圳的具體項目與百度開展合作,但雙方一直保持緊密的業務和研發層面的溝通。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.